HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance

Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization

Pre-IPO Beijing Airdoc Technology - The Strength and the Concerns

Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline

Pre-IPO Kindstar Globalgene Technology - A New Start with More Challenges

Pre-IPO Clarity Medical Group - The Prospects Are Still Not Brighter

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Capital Markets

<p>In 2012, DiNovA Capital introduced the world's only real-time image navigation technology to incubate <a href="https://www.smartkarma.com/entities/broncus-holding-corporation" target="_blank" data-smartkarma-citation="entities:33315:1" rel="noopener">Broncus (BRC HK)</a>. Neither the use of AI in the medical field nor interventional pulmonology or lung navigation was on the radar at that time. In about 9 years, Broncus has successfully developed the world’s first and only real-time image whole lung access augmented reality navigation system, which enabled the Company to build an integrated product portfolio for lung disease diagnosis and treatment supported by the navigation system. Meanwhile, it is worth mentioning that Broncus, which just completed the series D financing of about US$40 million in January this year, submitted the listing application to the HKEX. This insight mainly analyzed both the strength and the concerns of Broncus.</p>

In 2012, DiNovA Capital introduced the world's only real-time image navigation technology to incubate Broncus (BRC HK). Neither the use of AI in the medical field nor interventional pulmonology or lung navigation was on the radar at that time. In about 9 years, Broncus has successfully developed the world’s first and only real-time image whole lung access augmented reality navigation system, which enabled the Company to build an integrated product portfolio for lung disease diagnosis and treatment supported by the navigation system. Meanwhile, it is worth mentioning that Broncus, which just completed the series D financing of about US$40 million in January this year, submitted the listing application to the HKEX. This insight mainly analyzed both the strength and the concerns of Broncus.

Pre-IPO Broncus Holding Corporation - The Strength and the Concerns